Stock comparison
Jazz Pharmaceuticals
LeMaitre Vascular
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
JAZZ
Jazz Pharmaceuticals
Market cap
$15.05B
Sector
Healthcare
LMAT
LeMaitre Vascular
Market cap
$2.23B
Sector
Healthcare
Overall winner
LeMaitre Vascular LMAT
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | JAZZ | LMAT | Winner |
|---|---|---|---|
| Warren Buffett | 46D | 77B | LMAT |
| Benjamin Graham | 58D | 89A | LMAT |
| Philip Fisher | 42D | 81C | LMAT |
| Peter Lynch | 36D | 67B | LMAT |
| Joel Greenblatt | 44D | 56D | LMAT |
| Charlie Munger | 42D | 68D | LMAT |
| Terry Smith | 35D | 69D | LMAT |
Side-by-side metrics
| Metric | JAZZ | LMAT |
|---|---|---|
| Market cap | $15.05B | $2.23B |
| P/E (TTM) | 501.8x | 37.1x |
| EV/EBIT | 82.8x | 36.6x |
| ROIC (TTM) | -0.62% | 9.43% |
| Gross margin | 84.12% | 72.39% |
| Net margin | 0.66% | 24.35% |
| Revenue CAGR 5y | 8.37% | 12.75% |
| EPS CAGR 5y | - | 19.04% |
| Debt / Equity | 1.2x | 0.5x |
| Dividend yield | 0.0% | 0.84% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
JAZZ leads on
- Market cap$15.05Bvs $2.23B+85%
- Gross margin84.12%vs 72.39%+14%
LMAT leads on
- ROIC (TTM)9.43%vs -0.62%+107%
- Dividend yield0.84%vs 0.0%+100%
- Net margin24.35%vs 0.66%+97%
- P/E (TTM)37.1xvs 501.8x+93%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.